GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PharmaSGP Holding SE (XTER:PSG) » Definitions » EBIT

PharmaSGP Holding SE (XTER:PSG) EBIT : €29.3 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is PharmaSGP Holding SE EBIT?

PharmaSGP Holding SE's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was €8.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was €29.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PharmaSGP Holding SE's annualized ROC % for the quarter that ended in Sep. 2024 was 27.05%. PharmaSGP Holding SE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 2,822.17%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PharmaSGP Holding SE's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 11.48%.


PharmaSGP Holding SE EBIT Historical Data

The historical data trend for PharmaSGP Holding SE's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaSGP Holding SE EBIT Chart

PharmaSGP Holding SE Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
22.34 14.22 14.85 17.81 26.30

PharmaSGP Holding SE Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.61 7.17 7.24 6.64 8.28

Competitive Comparison of PharmaSGP Holding SE's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, PharmaSGP Holding SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaSGP Holding SE's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PharmaSGP Holding SE's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PharmaSGP Holding SE's EV-to-EBIT falls into.


;
;

PharmaSGP Holding SE EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €29.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmaSGP Holding SE  (XTER:PSG) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PharmaSGP Holding SE's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=30.816 * ( 1 - 25.36% )/( (94.378 + 75.71)/ 2 )
=23.0010624/85.044
=27.05 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

PharmaSGP Holding SE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=33.104/( ( (1.04 + max(-9.498, 0)) + (0.92 + max(0.386, 0)) )/ 2 )
=33.104/( ( 1.04 + 1.306 )/ 2 )
=33.104/1.173
=2,822.17 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(15.996 + 9.622 + 3.049) - (9.358 + 0 + 28.807)
=-9.498

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(15.971 + 10.959 + 2.755) - (16.136 + 0 + 13.163)
=0.386

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PharmaSGP Holding SE's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=29.325/255.402
=11.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmaSGP Holding SE EBIT Related Terms

Thank you for viewing the detailed overview of PharmaSGP Holding SE's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaSGP Holding SE Business Description

Traded in Other Exchanges
Address
Lochhamer Schlag 1, Graefelfing, Munich, DEU, 82166
PharmaSGP Holding SE is a pharmaceutical company. The company develops chemical-free, over-the-counter (OTC) drugs and healthcare products. The product portfolio includes RUBAXX for rheumatic pain Restaxil for nerve pain, and Deseo for sexual dysfunction. It has established various consumer brands in important indication areas, such as rheumatic and neuralgic pain or sexual weakness Also, the company offers products for skin aging and vertigo.
Executives
Dr. Clemens Fischer Supervisory Board
Madlena Hohlefelder Supervisory Board

PharmaSGP Holding SE Headlines

No Headlines